天然多亚型干扰素-αN1治疗慢性乙型肝炎的疗效观察

目的观察干扰素的抗病毒作用。方法用天然多亚型干扰素－αＮ１（惠福仁）治疗５０例慢性乙型肝炎，另５０例为对照组，两组临床与实验室指标均有可比性。治疗组用ＩＦＮ－αＮ１３ＭｕＩＭｑｄ治疗７ｄ，继用３ＭｕＩＭｔｉｗ治疗１１～２３周。结果经３个月治疗，治疗组与对照组的丙氨酸转氨酶复常率分别为８４％（４２５０）和４６％（２３５０），Ｐ＜０．０１；ＨＢｅＡｇ阴转率为５６．７％（１７３０）和１０．８％（４３７）；ＨＢＶＤＮＡ的阴转率为３６．４％（１２３３）和５．９％（１１７），Ｐ＜０．０１。结论ＩＦＮ－αＮ１治疗慢性乙型肝炎是目前疗效比较满意的抗病毒药，且副作用少，适于对其他干扰素疗效不佳的病例

An observation on antiviral effect of IFN--alpha N1 (Wellferon) in patients with chronic hepatitis B]

In order to observe the antiviral effect of IFN-alpha N1(Wellferon, British Glaxowellcome Company) on CHB, each 50 cases of CHB were selected as the therapy group and the control group. The patients in the therapy group were administrated with 3MU of IFN-alpha N1 once a day for one week, and then 3MU of IFN-alpha N1 three times weekly for 11-23 weeks, whereas the patients in the control group did not receive any antiviral treatment. At 3 months, the serum alanine transaminsae(ALT) was decreased to normal level in 84%(42/50) cases of the therapy group, while only in 46% (23/50) cases of the control group (P < 0.01). The negative seroconversion rate of HBeAg was 56.7% (17/30) and 10.8% (4/37), of HBV DNA was 36.4%(12/33) and 5.9% (1/17) in therapy and control groups respectively. There was obvious difference in two groups. The results suggest that IFN-alpha N1 is satisfying antiviral drug for CHB patients or patients non-responsive to other IFNs.